248 Chapter 8 81. Odenthal J, Rijpkema M, Bos D, Wagena E, Croes H, Grenman R, et al. Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma. Sci Rep 2018;8:10467. 82. Cortesina G, Martone T, Galeazzi E, Olivero M, De Stefani A, Bussi M, et al. Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer 2000;89:286-92. 83. Galeazzi E, Olivero M, Gervasio FC, De Stefani A, Valente G, Comoglio PM, et al. Detection of MET oncogene/ hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol 1997;254 Suppl 1:S138-43. 84. Jonker PKC, Metman MJH, Sondorp LHJ, Sywak MS, Gill AJ, Jansen L, et al. Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer: novel diagnostic tools for more selective central lymph node compartment dissection. Eur J Nucl Med Mol Imaging 2022;49:3557-70. 85. Liang M, Yang M, Wang F, Wang X, He B, Mei C, et al. Near-infrared fluorescence-guided resection of micrometastases derived from esophageal squamous cell carcinoma using a c-Met-targeted probe in a preclinical xenograft model. J Control Release 2021;332:171-83. 86. Madoz-Gurpide J, Zazo S, Chamizo C, Casado V, Carames C, Gavin E, et al. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med 2015;13:282.
RkJQdWJsaXNoZXIy MTk4NDMw